Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication

摘要: Tissue plasminogen activator (tPA) is the only approved therapy for acute ischemic stroke. However, delayed tPA treatment increases risk of cerebral hemorrhage and can result in exacerbation nerve injury. ADAMTS13, a von Willebrand factor (VWF) cleaving protease, has protective effect against brain injury may reduce bleeding by VWF. We examined whether ADAMTS13 longer therapeutic time window stroke than mice subjected to middle artery occlusion (MCAO). (0.1mg/kg) or (10mg/kg) was administered i.v., immediately after reperfusion 2-h 4-h MCAO comparison windows Infarct volume, hemorrhagic plasma high-mobility group box1 (HMGB1) levels blood flow were measured 24h MCAO. Both improved infarct volume without complications mice. On other hand, reduced HMGB1 levels, mice, but not effective these animals showed massive intracerebral hemorrhage. These results indicated that tPA, be useful as new agent